Immunotherapy in breast cancer: A clinician's perspective

Globally over 2 million women are diagnosed with breast cancer each year despite major advances in detection and treatment of the disease. Breast cancer is comprised of several distinct subtypes and understanding the heterogeneity of the disease has become crucial for treatment planning. Therapeutic...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sibapriya Chaudhuri, Scott Thomas, Pamela Munster
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/94c551c183164c3f9164d407cb037067
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:94c551c183164c3f9164d407cb037067
record_format	dspace
spelling	oai:doaj.org-article:94c551c183164c3f9164d407cb0370672021-12-01T05:06:27ZImmunotherapy in breast cancer: A clinician's perspective2667-005410.1016/j.jncc.2021.01.001https://doaj.org/article/94c551c183164c3f9164d407cb0370672021-06-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2667005421000028https://doaj.org/toc/2667-0054Globally over 2 million women are diagnosed with breast cancer each year despite major advances in detection and treatment of the disease. Breast cancer is comprised of several distinct subtypes and understanding the heterogeneity of the disease has become crucial for treatment planning. Therapeutic strategies span from a hormone therapy-based focus for women with estrogen receptor positive breast cancer to targeting human epidermal growth factor (HER2) by small molecules, antibody-drug-conjugates (ADC) and monoclonal antibodies in those with HER2 overexpression. Other novel treatment strategies for select subgroups of patients include the cyclin-dependent kinase 4/6 (CDK4/6) inhibitors for women with estrogen receptor positive tumors, the poly ADP ribose polymerase (PARP) inhibitors for those with BRCA mutations, and phosphoinositide 3-kinase (PI3K) inhibitors for women with tumors harboring phophatidylinositol-4,5-bisphosphate 3 kinase catalytic subunit alpha (PIK3CA) mutations. In contrast, the treatment for women with triple negative breast cancer has until recently been solely limited to chemotherapy. The profound impact of immunotherapy on cancer treatment in general has created much hope for its potential in breast cancer. This review will focus on the current advances and the research of immunotherapy in breast cancer, particularly on immune checkpoint inhibitors, adoptive cell transfer and cancer vaccines.Sibapriya ChaudhuriScott ThomasPamela MunsterElsevierarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENJournal of the National Cancer Center, Vol 1, Iss 2, Pp 47-57 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Sibapriya Chaudhuri Scott Thomas Pamela Munster Immunotherapy in breast cancer: A clinician's perspective
description	Globally over 2 million women are diagnosed with breast cancer each year despite major advances in detection and treatment of the disease. Breast cancer is comprised of several distinct subtypes and understanding the heterogeneity of the disease has become crucial for treatment planning. Therapeutic strategies span from a hormone therapy-based focus for women with estrogen receptor positive breast cancer to targeting human epidermal growth factor (HER2) by small molecules, antibody-drug-conjugates (ADC) and monoclonal antibodies in those with HER2 overexpression. Other novel treatment strategies for select subgroups of patients include the cyclin-dependent kinase 4/6 (CDK4/6) inhibitors for women with estrogen receptor positive tumors, the poly ADP ribose polymerase (PARP) inhibitors for those with BRCA mutations, and phosphoinositide 3-kinase (PI3K) inhibitors for women with tumors harboring phophatidylinositol-4,5-bisphosphate 3 kinase catalytic subunit alpha (PIK3CA) mutations. In contrast, the treatment for women with triple negative breast cancer has until recently been solely limited to chemotherapy. The profound impact of immunotherapy on cancer treatment in general has created much hope for its potential in breast cancer. This review will focus on the current advances and the research of immunotherapy in breast cancer, particularly on immune checkpoint inhibitors, adoptive cell transfer and cancer vaccines.
format	article
author	Sibapriya Chaudhuri Scott Thomas Pamela Munster
author_facet	Sibapriya Chaudhuri Scott Thomas Pamela Munster
author_sort	Sibapriya Chaudhuri
title	Immunotherapy in breast cancer: A clinician's perspective
title_short	Immunotherapy in breast cancer: A clinician's perspective
title_full	Immunotherapy in breast cancer: A clinician's perspective
title_fullStr	Immunotherapy in breast cancer: A clinician's perspective
title_full_unstemmed	Immunotherapy in breast cancer: A clinician's perspective
title_sort	immunotherapy in breast cancer: a clinician's perspective
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/94c551c183164c3f9164d407cb037067
work_keys_str_mv	AT sibapriyachaudhuri immunotherapyinbreastcanceracliniciansperspective AT scottthomas immunotherapyinbreastcanceracliniciansperspective AT pamelamunster immunotherapyinbreastcanceracliniciansperspective
_version_	1718405557222637568

Immunotherapy in breast cancer: A clinician's perspective

Ejemplares similares